Welcome to our dedicated page for Xencor news (Ticker: XNCR), a resource for investors and traders seeking the latest updates and insights on Xencor stock.
Xencor, Inc. develops engineered antibody therapeutics for cancer and autoimmune diseases using its XmAb technology platform and related antibody-engineering formats. News about XNCR commonly covers clinical and preclinical updates for XmAb drug candidates, including TL1A programs such as XmAb942 and XmAb412, T-cell engaging bispecific antibodies such as XmAb819 and XmAb541, and presentations of data at medical meetings.
Recurring company updates also include quarterly financial results, research-and-development priorities, collaboration and licensing activity, intellectual-property developments tied to Xtend Fc domain technology, and royalty matters involving partner-marketed medicines such as Ultomiris.
Xencor, Inc. (NASDAQ: XNCR) announced updated clinical data from its Phase 1 study of plamotamab, a bispecific antibody for treating B-cell malignancies, to be presented at the ASH Annual Meeting on December 12, 2021. The drug showed encouraging activity with an overall response rate (ORR) of 38.2% in diffuse large B-cell lymphoma and 80% in follicular lymphoma. Cytokine release syndrome was common but manageable. The company plans to initiate studies combining plamotamab with chemotherapy-free treatments starting late 2021 or early 2022.
Xencor, Inc. (NASDAQ:XNCR) announced updated results from its Phase 1 study of tidutamab, a bispecific antibody targeting neuroendocrine tumors (NETs). The study reported a recommended dosing regimen of 0.3 mcg/kg priming dose followed by 1.0 mcg/kg. At the data cut-off in August 2021, 41 patients were treated, with a 27% disease control rate. Tidutamab was well tolerated, with a low incidence of severe adverse effects. The drug is moving to a Phase 1b/2 study for Merkel cell carcinoma and small cell lung cancer, indicating potential advancements in treatment options.
Xencor, Inc. (NASDAQ:XNCR), a biopharmaceutical company specializing in engineered monoclonal antibodies and cytokines, has announced its participation in two investor conferences. The Credit Suisse 30th Annual Healthcare Conference will feature a presentation on November 9 at 2:40 p.m. ET. Additionally, the Jefferies London Healthcare Conference will have an on-demand presentation available starting November 18 at 8:00 a.m. GMT. Webcasts will be accessible on the company's website, with replays archived for at least 30 days.
Xencor, Inc. (NASDAQ: XNCR) will release its third quarter 2021 financial results after market close on November 8, 2021. The management will conduct a webcast and conference call at 4:30 p.m. ET to discuss results and provide a corporate update. Investors can access the call by dialing (877) 359-9508 for domestic callers or (224) 357-2393 for international callers. The call will also be available via a live webcast on their website, archived for 30 days.
Xencor has entered a second collaboration with Janssen Biotech to develop plamotamab, a bispecific antibody targeting CD20 x CD3 for B-cell malignancies. The deal includes a $100 million upfront payment and a $25 million equity investment from Johnson & Johnson. Xencor is eligible for royalties and milestone payments totaling up to $1.188 billion. The collaboration aims to enhance clinical trials and develop chemotherapy-free treatment regimens. A conference call is scheduled for 8:00 a.m. ET.
Xencor, Inc. (NASDAQ:XNCR) announced five poster presentations at the Society for Immunotherapy of Cancer's annual meeting from November 10-14, 2021. Key topics include clinical results for vudalimab, a PD-1 x CTLA-4 bispecific antibody, in various cancers, and data on preclinical programs targeting IL-12, PD-L1, TGFβR2, and NK cell engagement. The company aims to advance its dual checkpoint therapy in Phase 2 trials for advanced prostate cancer and gynecologic malignancies, indicating potential growth in its oncology pipeline.
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company focused on engineered monoclonal antibodies and cytokines, will present at the Cantor Virtual Global Healthcare Conference on September 27, 2021, at 4:00 p.m. ET. The event will be available via live webcast in the Investors section of their website. Xencor is currently developing 22 clinical candidates using its XmAb® technology, which enhances protein structure for innovative therapeutic actions. A replay of the presentation will be accessible for 30 days post-event.
Xencor, a clinical-stage biopharmaceutical company, reported significant financial results for Q2 2021, with total revenue soaring to $67.4 million, up from $13.1 million year-on-year. The company initiated a Phase 2 study for XmAb717 in metastatic prostate cancer and plans further studies for other drug candidates. R&D expenses increased to $49.5 million, reflecting ongoing development efforts. Xencor achieved a net income of $52.2 million, a turnaround from a net loss of $35 million in Q2 2020. The company aims to maintain cash reserves between $475 million and $500 million by year-end.
Xencor, a clinical-stage biopharmaceutical company focused on engineered monoclonal antibodies and cytokines for treating cancer and autoimmune diseases, has announced its participation in several investor events.
- Bernstein CD28 Day: Presentation on August 9 at 1:00 p.m. ET.
- Wedbush PacGrow Healthcare Conference: Panel on August 10 at 1:10 p.m. ET.
- BTIG Virtual Biotechnology Conference: Presentation on August 10 at 3:30 p.m. ET.
- Canaccord Genuity Conference: Presentation on August 11 at 4:30 p.m. ET.
- Piper Sandler West Coast Bus Tour: Presentation on August 12 at 4:00 p.m. ET.
A webcast of the Canaccord presentation will be available on Xencor's website.
Xencor, Inc. (NASDAQ: XNCR) will release its second quarter 2021 financial results post-market on August 4, 2021. A conference call is scheduled for 4:30 p.m. ET to discuss these results and provide a corporate update. The live call can be accessed via phone or a webcast on the company's website. Xencor is a clinical-stage biopharmaceutical firm focusing on engineered monoclonal antibodies and cytokines targeting cancer and autoimmune diseases, with 22 candidates in clinical development leveraging its XmAb® technology.